

# Les Indicateurs de l'oxygénation tissulaire

Dr Islem OUANES

Service de Réanimation Polyvalente  
CHU Fattouma Bourguiba Monastir

*Collège de Réanimation Médicale*

*Le 12/06/2013*

# Introduction

- L'oxygène (O<sub>2</sub>) alimente le fonctionnement de la mitochondrie.
- > 95% de l'O<sub>2</sub>:utilisé pour fabriquer l'ATP (source d'énergie).
- L'EDC est un déficit cellulaire aigu en O<sub>2</sub>.
- Objectifs macrovasculaires (PA, DC, RVS...): objectifs intermédiaires.
- Marqueurs de l'oxygénation tissulaire
- Microcirculation

# Définition microvasculaire du choc

Shock may be defined as a syndrome in which tissue perfusion is inadequate to meet the metabolic needs of the body. Because the most immediate metabolic nutrient is oxygen, this inadequate perfusion results in tissue hypoxia that has far-reaching effects on the whole organism, individual organ systems, tissue comprising the individual organ systems, and finally the individual cell. Cellular hypoxia leads to cell injury and the initiation of the inflammatory cascade. In situations where the tissue hypoperfusion is rapidly corrected, cell injury is limited; but if treatment is not provided in an expeditious fashion, the shock state may become irreversible with death of the organism. Thus the shock state should truly be viewed as a continuum from subclinical perfusion deficits to frank organ system dysfunction and death.

*Malhotra AK, Pathophysiology of shock. 2006.*

# Macrocirculation: partie émergente de l'ice-berg


Anomalies  
macrocirculatoires



# Vélocité microcirculatoire


©The McGraw-Hill Companies, Inc. Permission required for reproduction or display.

## Blood Vessel Types and Velocity of Blood Flow



# Pression microcirculatoire


## Blood Pressure and Distance



# **Bases physiopathologiques**

## **Oxygénation tissulaire**


# Respiration mitochondriale



# Lactates physiologiques ?

- GR= pas de mitochondries
- Le foie “respire” pour les globules rouges...


## Cycle de CORI




**Lactates= marqueur de l'oxygénation cellulaire**

**Delta  $\text{PCO}_2$ = marqueur de la balance entre le transport et besoins métaboliques**


# Hémodynamique-Oxygénation tissulaire



# Hémodynamique: Transport de l'O<sub>2</sub>



# Relations $TO_2$ - $VO_2$ - $EO_2$ -Lactates



## Relation SvO<sub>2</sub>-EO<sub>2</sub>

- $\text{VO}_2 = \frac{\cancel{\text{DCxHbx1,34x}}(\text{SaO}_2 - \text{SvO}_2)}{\cancel{\text{DCxHbx1,34x}}}$

- $\text{TaO}_2 = \underbrace{\cancel{\text{DCxHbx1,34x}} \text{SaO}_2}_{\text{CaO}_2}$

- $\text{EO}_2 = \text{VO}_2 / \text{TaO}_2$

- $\text{EO}_2 = (\text{SaO}_2 - \text{SvO}_2) / \text{SaO}_2$

Si SaO<sub>2</sub> est proche de 100%

↳  $\text{EO}_2 = 1 - \text{SvO}_2$

**SvO<sub>2</sub>=**

**marqueur de l'extraction  
et de l'oxygénation tissulaire globale**

# **Applications cliniques de monitoring de l'oxygénation tissulaire**

# Monitoring HD= utiliser les bons outils

- Bases physiologiques : ++
- Validité des outils : fiabilité de la mesure ?
- Validation des outils : intérêt clinique de l'outil ?

# Marqueurs d'O<sub>2</sub> utilisés en clinique

- SvO<sub>2</sub> et ScvO<sub>2</sub>
- Lactates
- Delta PCO<sub>2</sub>
- Tonométrie gastrique
- StO<sub>2</sub>

**SvO<sub>2</sub> et ScvO<sub>2</sub>**

# Définition SvO<sub>2</sub>

- SvO<sub>2</sub> : proportion d'Hb transportant de l'O<sub>2</sub> sur le sang veineux mêlé
- Reflet de la quantité d'O<sub>2</sub> non extraite par les tissus après satisfaction des besoins métaboliques de l'organisme
- Reflet global de l'oxygénation et de l'adéquation TaO<sub>2</sub>/VO<sub>2</sub>
- Recueil au niveau de l'artère pulmonaire
- Somme de tous les retours veineux de l'organisme (VCS, VCI, sinus coronaire)
- Disponible en continu


# SvO<sub>2</sub>: Problématique

- Mesure de la **SvO<sub>2</sub>** uniquement par cathétérisme artériel pulmonaire
  - ↳ Rapport bénéfice/risque incertain et controversé (monitorage invasif)
- **ScvO<sub>2</sub>** : saturation du sang veineux central
  - Recueil VCS ou OD, retour veineux de la partie supérieure de l'organisme, sur VVC avec adjonction fibre optique
  - Plus facilement utilisable et mesurable


# la ScvO<sub>2</sub> peut-elle remplacer la SvO<sub>2</sub> ?

**Pas d'équivalence numérique stricte mais :**

- Évolution parallèle
- Surestimation de la SvO<sub>2</sub> par la ScvO<sub>2</sub>
- Même pathogénicité



*Reinhart et al. Chest 1989; 95: 1216-1221*




*Reinhart et al. Intensive Care Med 2004*

# Surveillance continue de la SvO<sub>2</sub>: deux sites de mesure

- La SvO<sub>2</sub> du sang veineux mêlé : CAP + fibres optiques



- La SvO<sub>2</sub> centrale ou ScvO<sub>2</sub> : cathéter VCS + fibres optiques



# SvO2: Principes de mesure


## Spectrophotométrie

- Source de lumière rouge et infra rouge envoie des longueurs d'onde différentes, illumine le sang
- Réflexion lumière par GR (= selon le type Hb) par une fibre optique vers un photodétecteur ;
- Un logiciel calcule la SvO2




# Place de la SvO<sub>2</sub> en pratique clinique

## Early Goal directed therapy




# Place de la SvO<sub>2</sub> en pratique clinique

Inotropes use (H6)



In hospital mortality



# En résumé, la SvO<sub>2</sub> ...


- N'est pas physiologiquement régulée: pas de valeur « normale » (conséquence).
- Permet d'apprécier l'équilibre entre les besoins et les apports en O<sub>2</sub>.
- Méthode permettant d'évaluer en continu la finalité principale du DC: la délivrance d'O<sub>2</sub> aux tissus.
- Limite: mesure globale, ne prend pas en compte une souffrance tissulaire localisée.

# Circulations régionales

|                 | Q (%) | VO <sub>2</sub> (%) | EO <sub>2</sub> (%) | ScvO <sub>2</sub> (%) |
|-----------------|-------|---------------------|---------------------|-----------------------|
| <b>Peau</b>     | 15    | 5                   | 10                  | 90                    |
| <b>Reins</b>    | 25    | 10                  | 11                  | 89                    |
| <b>Viscères</b> | 25    | 25                  | 29                  | 71                    |
| <b>Muscles</b>  | 20    | 37                  | 53                  | 47                    |
| <b>SNC</b>      | 12    | 15                  | 36                  | 64                    |
| <b>Myocarde</b> | 3     | 8                   | 77                  | 23                    |

# Lactates et Pyruvates

# Relation entre Lactatémie et Mortalité Hospitalière chez les Patients en Etat Critique



Kruse JA. Intensive Care World 1987;4:121-5

# Lactates et Pronostic

## Feature Articles

### Early lactate clearance is associated with improved outcome in severe sepsis and septic shock\*

H. Bryant Nguyen, MD, MS; Emanuel P. Rivers, MD, MPH; Bernhard P. Knoblich, MD; Gordon Jacobsen, MS; Alexandria Muzzin, BS; Julie A. Ressler, BS; Michael C. Tomlanovich, MD

Table 3. Multivariate logistic regression modeling using statistically significant univariate variables associated with mortality

| Variable          | OR (95% CI)         | p Value          |
|-------------------|---------------------|------------------|
| Septic shock      | 2.473 (0.927–6.600) | .07              |
| Platelet          | 0.999 (0.994–1.004) | .69              |
| Prothrombin time  | 1.140 (0.988–1.315) | .07              |
| Albumin           | 0.569 (0.267–1.212) | .14              |
| Total bilirubin   | 1.045 (0.855–1.276) | .67              |
| Lactate           | 1.057 (0.945–1.182) | .34              |
| Lactate clearance | 0.989 (0.978–0.999) | .04 <sup>a</sup> |

OR, odds ratio; CI, confidence interval.

<sup>a</sup>Statistically significant,  $p < .05$ .

Lactate clearance

$$= \frac{(\text{Lactate}^{\text{ED Presentation}} - \text{Lactate}^{\text{Hour 6}}) \times 100}{\text{Lactate}^{\text{ED Presentation}}}$$

**L**actate clearance in the most proximal presentation of severe sepsis and septic shock is associated with improved morbidity and mortality rates.

Critical Care Medicine  
OFFICIAL JOURNAL OF THE SOCIETY OF CRITICAL CARE MEDICINE




Figure 1. Kaplan-Meier survival analysis between patients with lactate clearance <10 vs. ≥10% at 6 hrs after emergency department presentation.

111 patients

# Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock\*

Mark E. Mikkelsen, MD, MS; Andrea N. Miltiades, BA; David F. Gaieski, MD; Munish Goyal, MD; Barry D. Fuchs, MD; Chirag V. Shah, MD, MS; Scarlett L. Bellamy, ScD; Jason D. Christie, MD, MS

Crit Care Med 2009 Vol. 37, No. 5

## Lactates:

Low (<2), Intermediate (2–3.9), High (>4)




Figure 3. Association between serum lactate level and 28-day mortality, stratified by the presence of shock. Serum lactate categorized as follows: low = 0–1.9 mmol/L, intermediate (*Int*) = 2–3.9 mmol/L, and high =  $\geq 4$  mmol/L.

Table 4. Multivariable logistic regression demonstrating odds ratio of 28-day mortality by serum lactate strata in nonshock subgroup

|                 | Nonshock Model (n = 634) | Adjusted Odds Ratio<br>(95% Confidence Interval) | p         |
|-----------------|--------------------------|--------------------------------------------------|-----------|
| Lactate stratum |                          |                                                  |           |
| Low             |                          | Reference                                        | Reference |
| Intermediate    |                          | 2.05 (1.1–3.82)                                  | 0.024     |
| High            |                          | 4.87 (2.56–9.27)                                 | <0.001    |

Table 5. Multivariable logistic regression demonstrating odds ratio of 28-day mortality by serum lactate strata in overt shock

|                | Shock model (n = 196) | Adjusted Odds Ratio<br>(95% Confidence Interval) | p         |
|----------------|-----------------------|--------------------------------------------------|-----------|
| Lactate strata |                       |                                                  |           |
| Low            |                       | Reference                                        | Reference |
| Intermediate   |                       | 3.27 (1.18–9.05)                                 | 0.022     |
| High           |                       | 4.87 (1.87–12.66)                                | 0.001     |

# Lactates/pyruvates

- Le ratio Lactates/pyruvates pourrait orienter vers le mécanisme de l'hyperlactatémie:
- Hyperlactatémies dues à un déséquilibre  $TO_2-VO_2$ : **L/P élevé (>18)**
- Hyperlactatémies d'autres mécanismes : **L/P normal ou peu élevé**

Glycolyse aérobie, catécholamines (adrénaline), retard d'élimination...


# Lactates/pyruvates

SHOCK, Vol. 14, No. 1, pp. 8–12, 2000

## TIME-PATTERN OF LACTATE AND LACTATE TO PYRUVATE RATIO IN THE FIRST 24 HOURS OF INTENSIVE CARE EMERGENCY ADMISSIONS

Matti Suistomaa, Esko Ruukonen, Aarno Kari, and Jukka Takala

*Department of Intensive Care, Critical Care Research Program, Kuopio University Hospital, Kuopio, Finland*



## *En résumé: que faire des lactates en pratique clinique?*

- Un bon signe d'**alerte** et de **suivi**
- un marqueur **pronostique**
- Un **déséquilibre**: production/élimination

# Lactate Clearance vs Central Venous Oxygen Saturation as Goals of Early Sepsis Therapy

A Randomized Clinical Trial

JAMA. 2010;303(8):739-746

Alan E. Jones, MD

Nathan I. Shapiro, MD, MPH

Stephen Trzeciak, MD, MPH

Ryan C. Arnold, MD

Heather A. Claremont, BFA

Jeffrey A. Kline, MD

for the Emergency Medicine Shock Research Network (EMShockNet)

Investigators

## Objectifs:

- SvO<sub>2</sub> > 70%
- Lactate clearance > 10%

Lactate clearance=

$$\left[ \frac{\text{lactate}_{\text{initial}} - \text{lactate}_{\text{delayed}}}{\text{lactate}_{\text{initial}}} \right] \times 100\%$$

**Table 5.** Hospital Mortality and Length of Stay

| Variable                                    | Lactate Clearance Group (n = 150) | ScvO <sub>2</sub> Group (n = 150) | Proportion Difference (95% Confidence Interval) | P Value <sup>b</sup> |
|---------------------------------------------|-----------------------------------|-----------------------------------|-------------------------------------------------|----------------------|
| In-hospital mortality, No. (%) <sup>a</sup> |                                   |                                   |                                                 |                      |
| Intent to treat                             | 25 (17)                           | 34 (23)                           | 6 (−3 to 15)                                    |                      |
| Per protocol                                | 25 (17)                           | 33 (22)                           | 5 (−3 to 14)                                    |                      |
| Length of stay, mean (SD), d                |                                   |                                   |                                                 |                      |
| ICU                                         | 5.9 (8.46)                        | 5.6 (7.39)                        |                                                 | .75                  |
| Hospital                                    | 11.4 (10.89)                      | 12.1 (11.68)                      |                                                 | .60                  |
| Hospital complications                      |                                   |                                   |                                                 |                      |
| Ventilator-free days, mean (SD)             | 9.3 (10.31)                       | 9.9 (11.09)                       |                                                 | .67                  |
| Multiple organ failure, No. (%)             | 37 (25)                           | 33 (22)                           |                                                 | .68                  |
| Care withdrawn, No. (%)                     | 14 (9)                            | 23 (15)                           |                                                 | .15                  |

Noninferiority margin (Δ) at −10%.

**Delta PCO<sub>2</sub>**

# Delta PCO<sub>2</sub>

- **$\Delta\text{PCO}_2 = \text{PvCO}_2 - \text{PaCO}_2$**  ( $\text{PvCO}_2$  du sang veineux mêlé ou veineux central).
- Reflète la balance entre le  $\text{TO}_2$  et les besoins métaboliques.
- **La production du  $\text{CO}_2$ :**  $\text{VCO}_2 = \text{VO}_2 \times \text{R}$

R: Quotient respiratoire (1 ou 0,7 selon source d'énergie: glucides ou lipides).

- **En cas d'hypoxie** le  $\text{CO}_2$  est produit par le tamponnement de  $\text{H}^+$ :

Acidose lactique:  $\text{H}^+ + \text{HCO}_3^- \rightarrow \text{H}_2\text{O} + \text{CO}_2$

↳ Majoration de l'affinité de l'Hb au  $\text{CO}_2$  au détriment de l' $\text{O}_2$ : Effet Haldane.

$$\Delta\text{PCO}_2 = (\text{K} \times \text{VCO}_2) / \text{Débit cardiaque}$$

# Delta PCO<sub>2</sub>

Intensive Care Med (2005) 31:818–822  
DOI 10.1007/s00134-005-2602-8



ORIGINAL

Joseph Cuschieri  
Emanuel P. Rivers  
Michael W. Donnino  
Marius Katilios  
Gordon Jacobsen  
H. Bryant Nguyen  
Nikolai Pamukov  
H. Mathilda Horst

## Central venous-arterial carbon dioxide difference as an indicator of cardiac index

*Patients and participants: 83 consecutive ICU patients*

*Measurements: Simultaneous blood gases from the arterial, pulmonary artery (PA), and central venous (CV) catheters were obtained*




# Delta PCO<sub>2</sub>

Intensive Care Med (2002) 28:272–277  
DOI 10.1007/s00134-002-1215-8

ORIGINAL

Armand Mekontso-Dessap  
Vincent Castelain  
Nadia Anguel  
Mabrouk Bahloul  
Franck Schauvliege  
Christian Richard  
Jean-Louis Teboul

## Combination of venoarterial PCO<sub>2</sub> difference with arteriovenous O<sub>2</sub> content difference to detect anaerobic metabolism in patients



**Fig. 1** Receiver operating characteristic curves of the studied O<sub>2</sub>- and CO<sub>2</sub>-derived parameters for the prediction of hyperlactatemia (arterial lactate level  $\geq 2$  mmol/l)

# Tonométrie gastrique



# Tonométrie gastrique

Intensive Care Med (2001) 27: 317-319  
DOI 10.1007/s001340000666

## CURRENT TOPICS

G. Lebuffe  
E. Robin  
B. Vallet

### Gastric tonometry



$$PCO2_{gap} = P_gCO_2 - P_aCO_2 < 10 \text{ mmHg}$$

# Tonométrie gastrique

Gastric capnometry with air-automated tonometry predicts outcome in critically ill patients

Crit Care Med 2003; 31:474-80

Bruno Levy, MD, PhD; Pascale Gawalkiewicz, MD; Benoit Vallet, MD, PhD; Serge Briancon, MD, PhD; Lionel Nace, MD; Pierre-Edouard Bollaert, MD, PhD

Observational cohort study (n=95)

Relationship between  $PCO_2$  gap and mortality




Figure 1.  $PCO_2$  gap (mm Hg) in survivors (diamonds) and nonsurvivors (squares) during the study. \* $p < .05$  survivors vs. nonsurvivors. The numbers in italics indicate the actual number of patients who were monitored during that day.





Figure 4. Kaplan-Meier 28-day survival curves according to the  $PCO_2$  gap at hour 24.

# **Saturation tissulaire en oxygène (StO<sub>2</sub>)**

# StO2




**PROCÉDÉ DE MESURE : *Near Infra Red Spectroscopy (N.I.R.S.)***

# StO<sub>2</sub>

## Near infrared spectroscopy to assess systemic perfusion in the critically ill

Crawford J, Otero R, Goyal N, Sankey S, Rivers E. Crit Care Med. 2007;35(12, Abstract Supplement):A254.

StO<sub>2</sub>–ScvO<sub>2</sub> Scatter Plot at a Single Point in Time Measurement






# StO<sub>2</sub>

## Noninvasive muscle oxygenation to guide fluid resuscitation after traumatic shock

Crookes BA, Cohn SM, Burton EA, Nelson J, Proctor KG

*Surgery. 2004;135:662-70*



# Autres indicateurs de la microcirculation

- Capnographie sub-linguale (CO2 tissulaire)



- Microscopie spectrale polarisée orthogonale (MSPO)



# Conclusion

## *Marqueurs de l'oxygénation tissulaire:*

- Progrès technologique.
- Moyens non invasifs (au lit de malade).
- Mise en évidence de mécanismes physiopathologiques et de « nouveaux » concepts thérapeutiques (microcirculation).
- Objectifs thérapeutiques et marqueurs pronostique
- Etudes cliniques à large effectif.
- Réduction morbi-mortalité?